Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
20
BIAF Quote, Financials, Valuation and Earnings
Last price:
$1.23
Seasonality move
:
-21.35%
Day range:
$1.24 - $1.37
52-week range:
$1.18 - $46.53
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.85x
P/B ratio:
0.63x
Volume:
68.2K
Avg. volume:
87.8K
1-year change:
-95.74%
Market cap:
$5.6M
Revenue:
$9.4M
EPS (TTM):
-$16.13
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BIAF
bioAffinity Technologies, Inc.
|
$1.4M | -$2.70 | -39.97% | -1571.83% | -- |
|
FONR
FONAR Corp.
|
-- | -- | -- | -- | -- |
|
IMDX
Insight Molecular Diagnostics, Inc.
|
$285K | -$0.24 | -80.82% | -75.61% | $7.00 |
|
PRPH
ProPhase Labs, Inc.
|
$3.6M | -$0.15 | 3.99% | -50% | $13.80 |
|
VCYT
Veracyte, Inc.
|
$124.9M | $0.32 | 11.04% | 511.28% | $47.50 |
|
XWEL
XWELL, Inc.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BIAF
bioAffinity Technologies, Inc.
|
$1.24 | -- | $5.6M | -- | $0.00 | 0% | 0.85x |
|
FONR
FONAR Corp.
|
$14.52 | -- | $91.4M | 13.13x | $0.00 | 0% | 0.88x |
|
IMDX
Insight Molecular Diagnostics, Inc.
|
$5.41 | $7.00 | $155.1M | -- | $0.00 | 0% | 32.92x |
|
PRPH
ProPhase Labs, Inc.
|
$0.69 | $13.80 | $3.2M | -- | $0.00 | 0% | 0.47x |
|
VCYT
Veracyte, Inc.
|
$42.92 | $47.50 | $3.4B | 113.07x | $0.00 | 0% | 6.89x |
|
XWEL
XWELL, Inc.
|
$0.62 | -- | $3.6M | -- | $0.00 | 0% | 0.11x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BIAF
bioAffinity Technologies, Inc.
|
7.11% | -0.015 | 6.64% | 3.43x |
|
FONR
FONAR Corp.
|
18.59% | 1.654 | 49.09% | 9.64x |
|
IMDX
Insight Molecular Diagnostics, Inc.
|
-51.52% | -0.107 | 3.29% | 2.57x |
|
PRPH
ProPhase Labs, Inc.
|
52.83% | -0.268 | 40.4% | 0.07x |
|
VCYT
Veracyte, Inc.
|
3.12% | 1.341 | 1.49% | 5.74x |
|
XWEL
XWELL, Inc.
|
278.04% | 1.263 | 65.46% | 0.57x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BIAF
bioAffinity Technologies, Inc.
|
$390.5K | -$2.3M | -371.62% | -529.1% | -158.55% | -$2.5M |
|
FONR
FONAR Corp.
|
$10.4M | $3.2M | 4.68% | 5.84% | 12.26% | -$636K |
|
IMDX
Insight Molecular Diagnostics, Inc.
|
-$423K | -$7.7M | -1767.73% | -1008.03% | -2950% | -$5.6M |
|
PRPH
ProPhase Labs, Inc.
|
-$650.5K | -$4.8M | -51.85% | -90.24% | -539.52% | -$3.5M |
|
VCYT
Veracyte, Inc.
|
$89.4M | $23.1M | 2.43% | 2.52% | 17.53% | $42M |
|
XWEL
XWELL, Inc.
|
$1.3M | -$282K | -84.75% | -224.93% | -3.84% | -$3.1M |
bioAffinity Technologies, Inc. vs. Competitors
-
Which has Higher Returns BIAF or FONR?
FONAR Corp. has a net margin of -349.29% compared to bioAffinity Technologies, Inc.'s net margin of 10.25%. bioAffinity Technologies, Inc.'s return on equity of -529.1% beat FONAR Corp.'s return on equity of 5.84%.
Company Gross Margin Earnings Per Share Invested Capital BIAFbioAffinity Technologies, Inc.27% -$4.74 $9.6M FONRFONAR Corp.40.11% $0.34 $201.3M -
What do Analysts Say About BIAF or FONR?
bioAffinity Technologies, Inc. has a consensus price target of --, signalling upside risk potential of 14073.24%. On the other hand FONAR Corp. has an analysts' consensus of -- which suggests that it could fall by --. Given that bioAffinity Technologies, Inc. has higher upside potential than FONAR Corp., analysts believe bioAffinity Technologies, Inc. is more attractive than FONAR Corp..
Company Buy Ratings Hold Ratings Sell Ratings BIAFbioAffinity Technologies, Inc.0 1 0 FONRFONAR Corp.0 0 0 -
Is BIAF or FONR More Risky?
bioAffinity Technologies, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison FONAR Corp. has a beta of 1.000, suggesting its less volatile than the S&P 500 by 0.021000000000004%.
-
Which is a Better Dividend Stock BIAF or FONR?
bioAffinity Technologies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. FONAR Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. bioAffinity Technologies, Inc. pays -- of its earnings as a dividend. FONAR Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BIAF or FONR?
bioAffinity Technologies, Inc. quarterly revenues are $1.4M, which are smaller than FONAR Corp. quarterly revenues of $26M. bioAffinity Technologies, Inc.'s net income of -$5.1M is lower than FONAR Corp.'s net income of $2.7M. Notably, bioAffinity Technologies, Inc.'s price-to-earnings ratio is -- while FONAR Corp.'s PE ratio is 13.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for bioAffinity Technologies, Inc. is 0.85x versus 0.88x for FONAR Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BIAFbioAffinity Technologies, Inc.0.85x -- $1.4M -$5.1M FONRFONAR Corp.0.88x 13.13x $26M $2.7M
-
Which has Higher Returns BIAF or IMDX?
Insight Molecular Diagnostics, Inc. has a net margin of -349.29% compared to bioAffinity Technologies, Inc.'s net margin of -4174.62%. bioAffinity Technologies, Inc.'s return on equity of -529.1% beat Insight Molecular Diagnostics, Inc.'s return on equity of -1008.03%.
Company Gross Margin Earnings Per Share Invested Capital BIAFbioAffinity Technologies, Inc.27% -$4.74 $9.6M IMDXInsight Molecular Diagnostics, Inc.-162.69% -$0.34 -$6.1M -
What do Analysts Say About BIAF or IMDX?
bioAffinity Technologies, Inc. has a consensus price target of --, signalling upside risk potential of 14073.24%. On the other hand Insight Molecular Diagnostics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 29.39%. Given that bioAffinity Technologies, Inc. has higher upside potential than Insight Molecular Diagnostics, Inc., analysts believe bioAffinity Technologies, Inc. is more attractive than Insight Molecular Diagnostics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BIAFbioAffinity Technologies, Inc.0 1 0 IMDXInsight Molecular Diagnostics, Inc.1 2 0 -
Is BIAF or IMDX More Risky?
bioAffinity Technologies, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Insight Molecular Diagnostics, Inc. has a beta of 1.183, suggesting its more volatile than the S&P 500 by 18.332%.
-
Which is a Better Dividend Stock BIAF or IMDX?
bioAffinity Technologies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insight Molecular Diagnostics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. bioAffinity Technologies, Inc. pays -- of its earnings as a dividend. Insight Molecular Diagnostics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BIAF or IMDX?
bioAffinity Technologies, Inc. quarterly revenues are $1.4M, which are larger than Insight Molecular Diagnostics, Inc. quarterly revenues of $260K. bioAffinity Technologies, Inc.'s net income of -$5.1M is higher than Insight Molecular Diagnostics, Inc.'s net income of -$10.9M. Notably, bioAffinity Technologies, Inc.'s price-to-earnings ratio is -- while Insight Molecular Diagnostics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for bioAffinity Technologies, Inc. is 0.85x versus 32.92x for Insight Molecular Diagnostics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BIAFbioAffinity Technologies, Inc.0.85x -- $1.4M -$5.1M IMDXInsight Molecular Diagnostics, Inc.32.92x -- $260K -$10.9M
-
Which has Higher Returns BIAF or PRPH?
ProPhase Labs, Inc. has a net margin of -349.29% compared to bioAffinity Technologies, Inc.'s net margin of -774.52%. bioAffinity Technologies, Inc.'s return on equity of -529.1% beat ProPhase Labs, Inc.'s return on equity of -90.24%.
Company Gross Margin Earnings Per Share Invested Capital BIAFbioAffinity Technologies, Inc.27% -$4.74 $9.6M PRPHProPhase Labs, Inc.-73.67% -$1.65 $14.5M -
What do Analysts Say About BIAF or PRPH?
bioAffinity Technologies, Inc. has a consensus price target of --, signalling upside risk potential of 14073.24%. On the other hand ProPhase Labs, Inc. has an analysts' consensus of $13.80 which suggests that it could grow by 19987.34%. Given that ProPhase Labs, Inc. has higher upside potential than bioAffinity Technologies, Inc., analysts believe ProPhase Labs, Inc. is more attractive than bioAffinity Technologies, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BIAFbioAffinity Technologies, Inc.0 1 0 PRPHProPhase Labs, Inc.0 0 0 -
Is BIAF or PRPH More Risky?
bioAffinity Technologies, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ProPhase Labs, Inc. has a beta of -0.657, suggesting its less volatile than the S&P 500 by 165.684%.
-
Which is a Better Dividend Stock BIAF or PRPH?
bioAffinity Technologies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProPhase Labs, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. bioAffinity Technologies, Inc. pays -- of its earnings as a dividend. ProPhase Labs, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BIAF or PRPH?
bioAffinity Technologies, Inc. quarterly revenues are $1.4M, which are larger than ProPhase Labs, Inc. quarterly revenues of $883K. bioAffinity Technologies, Inc.'s net income of -$5.1M is higher than ProPhase Labs, Inc.'s net income of -$6.8M. Notably, bioAffinity Technologies, Inc.'s price-to-earnings ratio is -- while ProPhase Labs, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for bioAffinity Technologies, Inc. is 0.85x versus 0.47x for ProPhase Labs, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BIAFbioAffinity Technologies, Inc.0.85x -- $1.4M -$5.1M PRPHProPhase Labs, Inc.0.47x -- $883K -$6.8M
-
Which has Higher Returns BIAF or VCYT?
Veracyte, Inc. has a net margin of -349.29% compared to bioAffinity Technologies, Inc.'s net margin of 14.51%. bioAffinity Technologies, Inc.'s return on equity of -529.1% beat Veracyte, Inc.'s return on equity of 2.52%.
Company Gross Margin Earnings Per Share Invested Capital BIAFbioAffinity Technologies, Inc.27% -$4.74 $9.6M VCYTVeracyte, Inc.67.76% $0.24 $1.3B -
What do Analysts Say About BIAF or VCYT?
bioAffinity Technologies, Inc. has a consensus price target of --, signalling upside risk potential of 14073.24%. On the other hand Veracyte, Inc. has an analysts' consensus of $47.50 which suggests that it could grow by 10.67%. Given that bioAffinity Technologies, Inc. has higher upside potential than Veracyte, Inc., analysts believe bioAffinity Technologies, Inc. is more attractive than Veracyte, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BIAFbioAffinity Technologies, Inc.0 1 0 VCYTVeracyte, Inc.8 2 1 -
Is BIAF or VCYT More Risky?
bioAffinity Technologies, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Veracyte, Inc. has a beta of 1.829, suggesting its more volatile than the S&P 500 by 82.869%.
-
Which is a Better Dividend Stock BIAF or VCYT?
bioAffinity Technologies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Veracyte, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. bioAffinity Technologies, Inc. pays -- of its earnings as a dividend. Veracyte, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BIAF or VCYT?
bioAffinity Technologies, Inc. quarterly revenues are $1.4M, which are smaller than Veracyte, Inc. quarterly revenues of $131.9M. bioAffinity Technologies, Inc.'s net income of -$5.1M is lower than Veracyte, Inc.'s net income of $19.1M. Notably, bioAffinity Technologies, Inc.'s price-to-earnings ratio is -- while Veracyte, Inc.'s PE ratio is 113.07x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for bioAffinity Technologies, Inc. is 0.85x versus 6.89x for Veracyte, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BIAFbioAffinity Technologies, Inc.0.85x -- $1.4M -$5.1M VCYTVeracyte, Inc.6.89x 113.07x $131.9M $19.1M
-
Which has Higher Returns BIAF or XWEL?
XWELL, Inc. has a net margin of -349.29% compared to bioAffinity Technologies, Inc.'s net margin of -2.87%. bioAffinity Technologies, Inc.'s return on equity of -529.1% beat XWELL, Inc.'s return on equity of -224.93%.
Company Gross Margin Earnings Per Share Invested Capital BIAFbioAffinity Technologies, Inc.27% -$4.74 $9.6M XWELXWELL, Inc.17.32% -$0.26 $13M -
What do Analysts Say About BIAF or XWEL?
bioAffinity Technologies, Inc. has a consensus price target of --, signalling upside risk potential of 14073.24%. On the other hand XWELL, Inc. has an analysts' consensus of -- which suggests that it could grow by 1025.04%. Given that bioAffinity Technologies, Inc. has higher upside potential than XWELL, Inc., analysts believe bioAffinity Technologies, Inc. is more attractive than XWELL, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BIAFbioAffinity Technologies, Inc.0 1 0 XWELXWELL, Inc.0 0 0 -
Is BIAF or XWEL More Risky?
bioAffinity Technologies, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison XWELL, Inc. has a beta of 1.227, suggesting its more volatile than the S&P 500 by 22.697%.
-
Which is a Better Dividend Stock BIAF or XWEL?
bioAffinity Technologies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XWELL, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. bioAffinity Technologies, Inc. pays -- of its earnings as a dividend. XWELL, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BIAF or XWEL?
bioAffinity Technologies, Inc. quarterly revenues are $1.4M, which are smaller than XWELL, Inc. quarterly revenues of $7.3M. bioAffinity Technologies, Inc.'s net income of -$5.1M is lower than XWELL, Inc.'s net income of -$211K. Notably, bioAffinity Technologies, Inc.'s price-to-earnings ratio is -- while XWELL, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for bioAffinity Technologies, Inc. is 0.85x versus 0.11x for XWELL, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BIAFbioAffinity Technologies, Inc.0.85x -- $1.4M -$5.1M XWELXWELL, Inc.0.11x -- $7.3M -$211K
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
85
HUT alert for Dec 24
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
63
GPCR alert for Dec 24
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
Sell
32
SMX alert for Dec 24
SMX (Security Matters) Plc [SMX] is down 8.94% over the past day.
